The Interconnect® team is here to help

Your dedicated Care Coordinator will continue to keep you updated with important information about your patient's prescription. While your Care Coordinator is your primary contact, they are supported by a variety of people. To keep things running smoothly, you may hear from others on the team along the way.

Care Coordinator

Dedicated resource assigned to your office and patients

Support Care Coordinator

Assists with benefits investigations and facilitates prior authorizations

Registered Nurse

Expert on disease state education and the OCALIVA Prescribing Information

Territory Business Manager

In-office resource for questions about OCALIVA

Regional Access Manager

Dedicated access and reimbursement resource for your office

Director of Strategic Accounts

Works with payors to ensure coverage of OCALIVA

Meet your Care Coordinator

The same dedicated Care Coordinator that works with your office will also work with your patient to help things run smoothly from enrollment and start of treatment through ongoing adherence.

              

                                                         

                                             

                                                           

                                                                                                                                                      

                                                                                                                      

                                                                                                                                                                                                                                                           

Mercy A.

Mercy A.

Mercy A.

My email: mercy.a@interconnectsupport.com

My direct line: 1-732-649-7039

Interconnect main number: 1-844-622-4278

Some unique facts about me are that I have beautiful twin baby girls and I speak Ibo, a native Nigerian language.

My hobbies include going to the movies, shopping, and traveling.

One of my most memorable experiences as a Care Coordinator was when I helped one of my eligible patients receive her medication for a $0 co-pay. She was so happy and couldn’t stop thanking me. That feeling of knowing I can help someone and bring a smile to their face is the reason I do what I do.

Alice D.

Alice D.

Alice D.

My email: alice.d@interconnectsupport.com

My direct line: 1-732-649-7040

Interconnect main number: 1-844-622-4278

My hobbies are biking and hiking.

Some of my most memorable experiences at Interconnect® are when patients realize that I am truly there for them and tell me how grateful they are for my support.

Shaleema G.

Shaleema G.

Shaleema G.

My email: shaleema.g@interconnectsupport.com

My direct line: 1-844-622-4278

Interconnect main number: 1-844-622-4278

A unique fact about me is that I love to plan parties.

My hobbies include reading and planning events.

One of my most memorable experiences at Interconnect was hearing a patient cry with joy after finally getting approved for her medication after 2 rounds of appeals.

Camille H.

Camille H.

Camille H.

My email: camille.h@interconnectsupport.com

My direct line: 1-732-649-1616

Interconnect main number: 1-844-622-4278

A unique fact about me is that I like to collect hot pepper sauces when I travel.

My hobbies include reading, traveling, exploring new cuisines, spending time with family, and community service.

I care about helping people because it’s gratifying to know that I can positively impact other people. I want to make a difference!

Trupti P.

Trupti P.

Trupti P.

My email: trupti@interconnectsupport.com

My direct line: 1-732-649-7045

Interconnect main number: 1-844-622-4278

A unique fact about me is that I do not like to procrastinate at all. Whatever I’m doing, I jump right into it!

My hobbies include hiking, camping, reading, and watching movies.

As a Care Coordinator, I want to provide patients with superior customer service and help with access to medication.

Christina R.

Christina R.

Christina R.

My email: christina.r@interconnectsupport.com

My direct line: 1-732-649-7043

Interconnect main number: 1-844-622-4278

A unique fact about me is that I love to clean my house in my free time. It helps me relieve stress.

My hobbies include spending time with my family and 2 French bulldogs, and shopping at HomeGoods.

I care about helping people because dealing with a medical condition is hard enough without having to figure out confusing insurance coverage. If I can help alleviate some of the stress from a patient’s life, I feel like I’ve done my job.

Norma R.

Norma R.

Norma R.

My email: norma.r@interconnectsupport.com

My direct line: 1-732-649-1598

Interconnect main number: 1-844-622-4278

A unique fact about me is that I love decorating outside for the holidays. My nativity scene is very popular!

My hobbies include visiting tropical islands, ringing the bells at our church bell choir, walking my dogs, and playing in corn hole tournaments.

I care about helping people because I like speaking with patients and being an advocate for people with special needs.

Rick R.

Rick R.

Rick R.

My email: rick.r@interconnectsupport.com

My direct line: 1-732-649-1553

Interconnect main number: 1-844-622-4278

A unique fact about me is I play the trumpet.

My hobbies include working out, playing sports, listening to music.

As a Care Coordinator, I want to advocate for patients to help them get access to the treatment they need, and assist them with understanding insurance coverage.

Paul S.

Paul S.

Paul S.

My email: paul.s@interconnectsupport.com

My direct line: 1-732-649-1654

Interconnect main number: 1-844-622-4278

A unique fact about me is that I lived in the Philippines for 2 years.

My hobbies include exploring new cuisine, hiking, and working on computers.

One of my most memorable experiences as a Care Coordinator was when I realized that I am making a positive impact on patients’ lives by helping them get access to treatment.

Sarah S.

Sarah S.

Sarah S.

My email: sarah.s@interconnectsupport.com

My direct line: 1-732-649-1606

Interconnect main number: 1-844-622-4278

A unique fact about me is I play the flute.

My hobbies include reading, singing, spending time with loved ones.

As a Care Coordinator, I want to focus on finding the best possible solutions to assist patients with their needs.

Ross W.

Ross W.

Ross W.

My email: ross.w@interconnectsupport.com

My direct line: 1-732-649-1922

Interconnect main number: 1-844-622-4278

A unique fact about me is that I watch telenovelas by proxy.

My hobbies include word puzzles, board games, billiards, exploring foreign cultures, cooking, gardening, listening to music, and walking my dogs.

I care about helping people because there is a lot of information out there and I want to use my knowledge to be a valuable resource for those who might not be famililar.

Elizabeth J.

Elizabeth J.

Elizabeth J.

My email: elizabeth.j@interconnectsupport.com

My direct line: 1-732-649-7036

Interconnect main number: 1-844-622-4278

A unique fact about me is that I love to sing!

My hobbies include traveling and going on cruises, listening to music, rooting for my favorite football and baseball teams, and playing games on my PS4.

As a Care Coordinator, I want to assist patients compassionately throughout their treatment, and help them navigate the information, resources, financial assistance and support that is available through Interconnect®.


Not in this location?

Find a Care Coordinator in a different ZIP code.

Stay Interconnected

If you currently treat PBC and would like to connect with us to learn more, please complete the form below:

Thank You

Thank you for signing up!

Be on the lookout for news and updates about OCALIVA.

Expand Collapse

Indication and Important Safety Information

Warning: Hepatic decompensation and failure in incorrectly dosed PBC patients with Child-Pugh Class B or C or decompensated cirrhosis

In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with Primary Biliary Cholangitis (PBC) with decompensated cirrhosis or Child-Pugh Class B or C hepatic impairment when OCALIVA was dosed more frequently than recommended. The recommended starting dosage of OCALIVA is 5 mg once weekly for patients with Child-Pugh Class B or C hepatic impairment or a prior decompensation event.

Indication

OCALIVA is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.

This indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP). An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Contraindications

OCALIVA is contraindicated in patients with complete biliary obstruction.

Warnings and Precautions

Hepatic Decompensation and Failure in Incorrectly-Dosed PBC Patients with Child-Pugh Class B or C or Decompensated Cirrhosis

In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with decompensated cirrhosis or Child-Pugh B or C hepatic impairment when OCALIVA was dosed more frequently than the recommended starting dosage of 5 mg once weekly. Reported cases typically occurred within 2 to 5 weeks after starting OCALIVA and were characterized by an acute increase in total bilirubin and/or ALP concentrations in association with clinical signs and symptoms of hepatic decompensation (e.g., ascites, jaundice, gastrointestinal bleeding, worsening of hepatic encephalopathy). Patients who died due to liver-related complications generally had decompensated cirrhosis prior to treatment and were started on OCALIVA 5 mg once daily, which is 7-fold greater than the once-weekly starting regimen in this population.

Routinely monitor patients for progression of PBC disease, including liver-related complications, with laboratory and clinical assessments. Dosage adjustment, interruption or discontinuation may be required. Close monitoring is recommended for patients at an increased risk of hepatic decompensation. Severe intercurrent illnesses that may worsen renal function or cause dehydration (e.g., gastroenteritis), may exacerbate the risk of hepatic decompensation. Interrupt treatment with OCALIVA in patients with laboratory or clinical evidence of worsening liver function indicating risk of decompensation, and monitor the patient’s liver function. Consider discontinuing OCALIVA in patients who have experienced clinically significant liver-related adverse reactions. Discontinue OCALIVA in patients who develop complete biliary obstruction.

Liver-Related Adverse Reactions

Dose-related, liver-related adverse reactions including jaundice, worsening ascites and primary biliary cholangitis flare have been observed in clinical trials, as early as one month after starting treatment with OCALIVA 10 mg once daily up to 50 mg once daily (up to 5-times the highest recommended dosage). Monitor patients during treatment with OCALIVA for elevations in liver biochemical tests and for the development of liver-related adverse reactions.

Severe Pruritus

Severe pruritus was reported in 23% of patients in the OCALIVA 10 mg arm, 19% of patients in the OCALIVA titration arm, and 7% of patients in the placebo arm in a 12-month double-blind randomized controlled trial of 216 patients. Severe pruritus was defined as intense or widespread itching, interfering with activities of daily living, or causing severe sleep disturbance, or intolerable discomfort, and typically requiring medical interventions. Consider clinical evaluation of patients with new onset or worsening severe pruritus. Management strategies include the addition of bile acid resins or antihistamines, OCALIVA dosage reduction, and/or temporary interruption of OCALIVA dosing.

Reduction in HDL-C

Patients with PBC generally exhibit hyperlipidemia characterized by a significant elevation in total cholesterol primarily due to increased levels of high-density lipoprotein-cholesterol (HDL-C). Dose-dependent reductions from baseline in mean HDL-C levels were observed at 2 weeks in OCALIVA-treated patients, 20% and 9% in the 10 mg and titration arms, respectively, compared to 2% in the placebo arm. Monitor patients for changes in serum lipid levels during treatment. For patients who do not respond to OCALIVA after 1 year at the highest recommended dosage that can be tolerated (maximum of 10 mg once daily), and who experience a reduction in HDL-C, weigh the potential risks against the benefits of continuing treatment.

Adverse Reactions

The most common adverse reactions occurring in ≥5% of subjects taking OCALIVA were pruritus, fatigue, abdominal pain and discomfort, rash, oropharyngeal pain, dizziness, constipation, arthralgia, thyroid function abnormality, and eczema.

Drug Interactions

  • Bile Acid Binding Resins
    Bile acid binding resins such as cholestyramine, colestipol, or colesevelam adsorb and reduce bile acid absorption and may reduce the absorption, systemic exposure, and efficacy of OCALIVA. If taking a bile acid binding resin, take OCALIVA at least 4 hours before or 4 hours after taking the bile acid binding resin, or at as great an interval as possible.
  • Warfarin
    The International Normalized Ratio (INR) decreased following coadministration of warfarin and OCALIVA. Monitor INR and adjust the dose of warfarin, as needed, to maintain the target INR range when coadministering OCALIVA and warfarin.
  • CYP1A2 Substrates with Narrow Therapeutic Index
    Obeticholic acid, the active ingredient in OCALIVA, may increase the exposure to concomitant drugs that are CYP1A2 substrates. Therapeutic monitoring of CYP1A2 substrates with a narrow therapeutic index (e.g. theophylline and tizanidine) is recommended when coadministered with OCALIVA.
  • Inhibitors of Bile Salt Efflux Pump
    Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP) such as cyclosporine. Concomitant medications that inhibit canalicular membrane bile acid transporters such as the BSEP may exacerbate accumulation of conjugated bile salts including taurine conjugate of obeticholic acid in the liver and result in clinical symptoms. If concomitant use is deemed necessary, monitor serum transaminases and bilirubin.

Please see Full Prescribing Information, including Boxed WARNING for OCALIVA. Rx only.

To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.